Email ID
Password
Scrip   
MedImmune licenses antibodies from Trellis
02 December 2009
Simon Varcoe

MedImmune has acquired the worldwide rights to develop and commercialise Trellis Bioscience's antibodies that are directed against the respiratory syncytial virus (RSV).

The biologics unit of AstraZeneca will pay Trellis an up-front cash amount and make additional payments for potential development,...



Please Login to read the full article.
JOB OF THE WEEK Promote your vacancy here
© 2010 Informa plc. All rights reserved.
This site is owned and operated by Informa plc ("Informa") whose registered office is Mortimer House, 37-41 Mortimer Street, London, W1T 3JH. Registered in England and Wales. Number 3099067. UK VAT Group: GB 365 4626 36